Rinsho Ketsueki
Online ISSN : 1882-0824
Print ISSN : 0485-1439
ISSN-L : 0485-1439
Search
Advanced search
OR
Browse
Search
Volume 47, Issue 5
Displaying 1-12 of 12 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
Picture in Clinical Hematology
The 46th Annual Meeting of the Japanese Society of Clinical Hematology
Special Award Received Lecture
The 67th Annual Meeting of the Japanese Society of Hematology / The 47th Annual Meeting of the Japanese Society of Clinical Hematology
Symposium
Education Lecture
A Case Report
  • Successful platelet recovery after the second eradication of Helicobacter pylori with metronidazole in two patients with chronic idiopathic thrombocytopenic purpura
    Toru TAKAHASHI, Katsuhiro HATAO, Koji YAMADA
    2006 Volume 47 Issue 5 Pages 392-395
    Published: May 30, 2006
    Released on J-STAGE: March 14, 2008
    DOIhttps://doi.org/10.11406/rinketsu.47.392
    JOURNAL RESTRICTED ACCESS
    Show abstractHide abstract
    There are many reports on the efficacy of Helicobacter pylori (H. pylori) eradication therapy in patients with H. pylori-positive chronic idiopathic thrombocytopenic purpura (ITP). We administrated metronidazole (MNZ), amoxicillin (AMPC), and a proton-pump inhibitor (PPI) as the second eradication therapy for two patients who failed in the first eradication therapy consisting of PPI, AMPC, and clarithromycin (CAM). Successful eradication and the rapid recovery of platelet counts within one month were achieved in both patients. Recently, H. pylori eradication is considered as the first-line therapy for H. pylori-positive chronic ITP patients. In Japan, the PPI+AMPC+CAM regimen is recognized as the standard eradication therapy for H. pylori. However, the PPI+AMPC+MNZ regimen is also useful for eradication and should be tried as the re-treatment regimen after failure of the first-line CAM-containing regimen.
    View full abstract
    Download PDF (557K)
Short Reports
  • Subacute necrotizing lymphadenitis showing lymphatic blockade-mediated acute respiratory failure
    Yasuo AOTA, Tomotaka IGUCHI, Yuko SASAKI, Tomohisa YOKOYAMA, Nahoko SH ...
    2006 Volume 47 Issue 5 Pages 396-398
    Published: May 30, 2006
    Released on J-STAGE: March 14, 2008
    DOIhttps://doi.org/10.11406/rinketsu.47.396
    JOURNAL RESTRICTED ACCESS
    Show abstractHide abstract
    A 24-year-old woman was referred to our hospital with fever and cervical lymphadenopathy. On admission, her serum concentration of soluble IL-2 receptor had increased to 1,740 IU/ml, LDH was 2,889 IU/l, and ferritin was 2,389 ng/ml. Dyspnea became evident (PaO2 60 Torr) with a further increase of serum ferritin to 96,552 mg/ml on day 11. Chest CT findings showed the thickening of the interlobular septa, bilateral pleural effusion, and swelling of mediastinal lymph nodes, symptoms which were very similar to those associated with lymphangitis carcinomatosis. She received steroid pulse therapy (methylprednisolone, 1,000 mg/day for three days). This resulted in a rapid improvement of her dyspnea and disappearance of the lymphatic blockade-mediated pulmonary findings in two days. A cervical lymph node biopsy was performed on day 12, and revealed that she had subacute lymphadenitis (Kikuchi disease). This case suggests that acute respiratory failure should be considered in cases of Kikuchi disease when associated with a lymphatic blockade.
    View full abstract
    Download PDF (845K)
  • Complication of topoisomerase II inhibitor-related acute promyelocytic leukemia with t(1;10) (q21;q26) in a patient with Sézary syndrome
    Natsuki MIYOSHI, Masaaki NODA
    2006 Volume 47 Issue 5 Pages 399-401
    Published: May 30, 2006
    Released on J-STAGE: March 14, 2008
    DOIhttps://doi.org/10.11406/rinketsu.47.399
    JOURNAL RESTRICTED ACCESS
    Show abstractHide abstract
    A 74-year-old man was diagnosed as having Sézary syndrome in 1999. Treatment with combination chemotherapy could not completely control both the erythroderma and Sézary cells. However, treatment with oral administration of etoposide was able to maintain the patient in a good condition for about 4 years. In June 2004, he developed topoisomerase II inhibitor-related acute promyelocytic leukemia. Chromosomal analysis demonstrated abnormalities of t(1;10) (q21;q26) and t(15;17) (q22;q12) in 17 of 20 cells. Despite treatment with ATRA and combination chemotherapy, the patient died of brain hemorrhage.
    View full abstract
    Download PDF (511K)
 
 
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top